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Serious infection affects around 20% of patients who present febrile and neutropenic1. Febrile 
neutropenia is thus a well-recognised medical emergency. Addressing the challenges of both rapid 
delivery of antibiotics to patients at risk of life-threatening sepsis, as well as appropriate antibiotic 
stewardship to reduce antibiotic overuse, continue to keep this a priority for clinicians, patients and 
parents. Audits of febrile neutropenia (FN) practice have previously demonstrated variation in 
definitions for FN and its management
1,2
.
 
In September 2012, the National Institute for Clinical 
Excellence (NICE) published the ‘Neutropenic sepsis: prevention and management of neutropenic 
sepsis in cancer patients’3 guideline and we sought to assess if this has reduced variations in practice. 
This re-audit included 45 UK centres (14 CCLG principal treatment centres). The centres completed 
questionnaires regarding their febrile neutropenia policy and any admissions over a 2 week period in 
March 2015. 108 episodes from 30 centres were recorded ranging from 0-10 episodes per centre.  
The results show continued variability in definition and management. The NICE suggested definition 
of FN (temperatures > 38 °C and neutrophil count of <0.5) is used by 21/43 (49%) centres (see table 
1). Only 19/45 (42%) centres use risk stratification at admission (a modified Alexander approach in 
16 centres, as suggested by NICE, with one centre using the SPOG model4 and two setting up their 
own stratification system).  
The NICE guideline suggests patients presenting with FN should have central and peripheral blood 
cultures and blood tests including CRP and lactate. Central blood cultures were sent in over 90% of 
episodes and 19% of episodes had peripheral blood cultures performed but only two centres routinely 
performed paired blood cultures. CRP was analysed in 83% of episodes but lactate in only 15% of 
admissions with 6 centres routinely testing lactate on presentation.  
37% centres use single agent piperacillin/tazobactam as initial antibiotic treatment, 34% use 
piperacillin/tazobactam with an aminoglycoside and 13% meropenem alone. Overall, 62% of 
inpatients received their antibiotics within 60 minutes of admission or febrile episode. 9 of 17 centres 
with multiple admissions over the 2 week period administered the first dose of antibiotic within 60 
minutes in ≥ 80% of occasions. 
44 (40%) episodes were assessed as low risk at 48hrs with 28 (64%) switching to oral antibiotics and 
16 (36%) continuing IV therapy. Antibiotics were stopped upon resolution of fever irrespective of 
neutrophil count in 75%, whilst 14% appropriately continued antibiotics to treat a confirmed 
infection. In 11% of episodes the reason for continuation of antibiotics was unclear. 
The results show continuing variation in practice and a lack of adherence to NICE guidance. The 
variance has not significantly changed since the previous audit in 2012. Participating centres have 
been sent the results plus centre specific analysis to see their results in comparison to national practice 
and guidelines. A re-audit is planned for 2016. The adoption of a national policy on neutropenic 
sepsis management based on the best available evidence of clinical effectiveness and cost-
effectiveness requires local implementation but should improve outcomes. 
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Table 1: Definitions reported to be used for defining febrile neutropenia 
 
Definitions of febrile neutropenia 
 Neutrophil count 
Temperature cutoff <0.5 <0.5 or <1 and 
falling 
<0.75 <1 
>38.5°C or 2 measurements >38.0°C 1 hour or 
more apart 
1 2 1 1 
>38.5°C or 2 measurements >38.0°C 4 hour or 
more apart 
2  2  
>38°C 21* 4 5 4 
 
* NICE recommended definition 
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